{
  "id": 9632883,
  "title": "FDA Approves New Option for Previously Treated Bile Duct Cancer",
  "url": "https://urgent.news/2026/09/24/fda-approves-new-option-for-previously-treated-bile-duct-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T20:56:41.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/othercancers/123137"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- The FDA approved the oral fibroblast growth factor receptor 2 (FGFR2) inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangements, the agency announced...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}